Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.

doi:10.1016/j.jtho.2025.10.012

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2026

Chen Monica F, Lee Jake June-Koo, Choudhury Noura J, Hui Angela B, Jeng Mark Y, Zheng Jennifer, Aly Rania G, Sielski Neil, Ahn Linda, Pupo Amanda, Nesselbush Monica C, Jabara Isabel, Wilcox Jessica A, Santomasso Bianca D, Lin Andrew L, Schaff Lauren, Chaft Jamie E, Riely Gregory J, Kris Mark G, Arfe Andrea, Yang Soo-Ryum, Young Robert J, Diehn Maximilian, Boire Adrienne, Yu Helena A

Abstract excerpt

INTRODUCTION: Despite improved central nervous system (CNS) disease control with osimertinib, 20% of patients will develop CNS progression. Amivantamab and lazertinib have demonstrated activity in patients with EGFR-mutant lung cancer. This trial evaluated amivantamab and lazertinib in patients with new or progressive CNS metastases after prior therapy (NCT04965090). METHODS: We evaluated amivantamab and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Meningeal Carcinomatosis

Share to Meningeal Neoplasms

Share to Quinolines

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 41139066
DOI: 10.1016/j.jtho.2025.10.012

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases.PMID 41139066Read ↗

Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.Semantic proximity Read ↗

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.Semantic proximity Read ↗

Leptomeningeal metastases in non-small-cell lung cancer.Semantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.Semantic proximity Read ↗

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A.Semantic proximity Read ↗

EGFR-mutated non-small lung cancer brain metastases and radiosurgery outcomes with a focus on leptomeningeal disease.Semantic proximity Read ↗

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.Semantic proximity Read ↗

Salvage dacomitinib plus intraventricular pemetrexed for leptomeningeal metastasis after failure of third‑generation EGFR‑TKIs in EGFR‑mutant NSCLC: an ambispective cohort study.Semantic proximity Read ↗

Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.Semantic proximity Read ↗

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.Semantic proximity Read ↗

High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.